5-methoxy-1-methyl-1H-pyrazol-4-amine | 1393100-53-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-methoxy-1-methyl-1H-pyrazol-4-amine
• 英文别名: 5-Methoxy-1-methyl-1H-pyrazol-4-amine；5-methoxy-1-methylpyrazol-4-amine
• CAS: 1393100-53-2
• 化学式: C₅H₉N₃O
• 分子量: 127.146
• InChiKey: IYHZZSYZWZWDGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-methyl-1H-pyrazol-4-amine 、 2-(1-ethyl-3-iodo-1H-indazol-6-yl)propan-2-ol 生成 2-{1-ethyl-3-[(5-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-1H-indazol-6-yl}propan-2-ol
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  公开号：

  US20230322683A1
• 作为产物：
  描述：

  5-methoxy-1-methyl-4-nitro-1H-pyrazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 以99 mg的产率得到5-methoxy-1-methyl-1H-pyrazol-4-amine
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  公开号：

  US20230322683A1

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20230322683A1

  公开（公告）日：2023-10-12

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.